ClinicalTrials.gg
Active, not recruitingNCT06681181Updated Aug 26, 2026

A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK4528287 in Healthy Participants

A Phase 1 interventional study of GSK4528287 and Placebo in Colitis, Ulcerative, sponsored by GlaxoSmithKline. Active, not recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Colitis, Ulcerative by GlaxoSmithKline — 2 open to participants now, 3 under way, none of them phase 3. Colitis, Ulcerative · GlaxoSmithKline.

Enrollment
5th of 15
48 · median 16
Started
2024
with 1 other
Phase 1
10 of 16
2 open now
Registered
14th of 16
by date

Among the 16 studies in Colitis, Ulcerative by GlaxoSmithKline, this one is the 5th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2024, is one of 10 in phase 1, and was the 14th registered.

Colitis, Ulcerative

1,856 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

2 of the 16 studies in Colitis, Ulcerative by GlaxoSmithKline are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 306 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 135 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Colitis, Ulcerative by GlaxoSmithKline, or all of them as a file.
02

Study summary

"GSK4528287 is a drug being developed to treat like inflammatory bowel diseases like Crohns disease and ulcerative colitis. This study is the first time that GSK4528287 will be given to humans. The study will test single doses of GSK4528287 to check for side effects, measure blood levels, and understand how it works in the body. The study will start with a small dose, and the dose will be increased for each new group of participants."

03

Conditions studied

  • Colitis, Ulcerative

Keywords

  • Inflammatory bowel disease
  • Crohns disease
  • Ulcerative colitis
  • GSK4528287
  • First time in human (FTIH)
  • Healthy participants
  • GlaxoSmithKline (GSK)
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring
  • White blood cell greater than or equal to (>=) lower limit of normal (LLN), including both lymphocyte counts >= LLN and >= LLN, at both screening and pre-dose (Day-1) Note: in cases where the test is abnormal, the participant may have the test repeated once and if their second test is normal, they will be eligible. In the event a second test is also abnormal, the participant is not eligible
  • (ECG) with no abnormality at the discretion of the investigator/designee
  • Participants with a confirmed positive vaccination status for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines as per local/site guidance
  • SARS-CoV-2 screening test negative as per local guidance
  • If dosing is during influenza season (October to April per local guidelines), participants who have not had a seasonal influenza vaccine must receive a medicines and healthcare products regualtory agency (MHRA)-approved influenza vaccine at least 30 days before dosing
  • Body weight >= 50 kilograms (kg) and (BMI) within the range 18-32 kilograms per square meters (kg/m\^2) (inclusive)
  • Male and/or female of non-
  • Male participants are eligible to participate if they agree to the following during the study intervention period and for 48 weeks after the single dose of study intervention: refrain from donating sperm; be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent; or agree to use a male condom and should also be advised of the benefit for a female partner to use a highly effective method of as a condom may break or leak when having sexual intercourse with a woman of childbearing potential (WOCBP) who is not currently pregnant
  • A female participant is eligible to participate if she is a woman of non-childbearing potential (WONCBP)
  • Capable of giving signed

Exclusion criteria

Exclusion Criteria:

  • History or presence of/significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data
  • Abnormal blood pressure as determined by the investigator
  • Symptomatic herpes zoster within 3 months prior to screening
  • Prior medical history of anaphylaxis or severe adverse reactions to vaccines
  • Significant allergies to humanized monoclonal antibodies
  • multiple or severe drug allergies, intolerance to topical , or severe post-treatment reactions (including, but not limited to, erythema multiforme major, linear Immunoglobulin A [IgA] dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis)
  • Immunodeficiency or autoimmunity assessed by medical history.
  • A history of recurrent infections
  • Treatment of any significant infection within 3 months prior to the first dose of study drug, including both serious local infection (e.g., cellulitis, abscess) or systemic infection (e.g., pneumonia, shingles)
  • Any history of chronic infection including tuberculosis, , or (HIV)
  • Any acute infection (including upper respriatory tract infection [URTI] and urinary tract infection [UTI]) which has not fully resolved within four weeks of dosing
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GlaxoSmithKline (GSK) medical monitor, poses a safety risk with regards to participation in the trial
  • History of , including malignant or non-malignant skin cancer
  • Prior moderate/severe SARS-CoV-2 infection requiring oxygen supplementation or admission to hospital
  • Treatment with biologic agents (such as monoclonal antibodies including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to dosing
  • Antibiotics or antiviral therapy within 30 days of dosing
  • Receipt of within 1 month prior to screening or plan to receive live vaccination during the study
  • Past or intended use of over the counter or prescription medication including herbal medications within 7 days prior to dosing
  • The participant has participated in a clinical trial and has received an product (IP) within the following time-period prior to the first dosing day of the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer)
  • Exposure to more than 4 new chemical entities within 12 months prior to dosing
  • Current enrolment or past participation in this clinical study.
  • Participation in a clinical study that would result in donation of blood or blood products in excess of 500 millilitres (mL) within a 56 day period
  • A positive diagnostic Mycobacterium tuberculosis bacteria (MTB) test at screening (defined as positive QuantiFERON Gold test)
  • Positive test for HIV antibody at screening
  • Positive drug/alcohol test, including tetrahydrocannabinol, at screening or Day 1
  • Positive smoke breath analyzer levels indicative of smoking history at screening and in house admission to the clinical research unit or regular use of tobacco- or nicotine-containing products (e.g., nicotine patches, vaporizing devices) within 6 months prior to screening
  • A positive confirmation of SARS CoV 2 infection or signs and symptoms suggestive of SARS CoV 2 at screening or pre dose
  • The participant is at high risk of MTB infection in the opinion of the Investigator. Risk factors include residing in a high prevalence area or having close contact with a person with confirmed MTB infection
  • The participant has a phobia to needles
  • Regular alcohol consumption within 6 months prior to study, defined as: An average weekly intake of greater than (>)14 units of alcohol. One unit is equivalent to 8 grams (g) of alcohol: a half pint (approximately 240 mL) of beer, 1 glass (125 mL) of wine or 1 measure (25 mL) of spirits
  • Regular use of known drugs of abuse, including tetrahydrocannabinol
  • (ALT or AST) >1.0* (ULN)
  • Total >1.0*ULN; Participants with Gilbert's syndrome can be included with total bilirubin >1.5*ULN as long as direct bilirubin is less than or equal to (\<=) 1.5*ULN
  • Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • Presence of hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) at screening or Day -1 or within 3 months prior to first dose of study intervention.
  • Positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention.
  • Positive hepatitis C ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study intervention.
  • (QT interval corrected for heart rate according to Fredericia's formula) >450 milliseconds (msec).
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Cohort 1: Dose 1

    Participants will be administered Dose 1 of GSK4528287.

    Drug: GSK4528287

  • Experimental
    Cohort 2: Dose 2

    Participants will be administered Dose 2 of GSK4528287.

    Drug: GSK4528287

  • Experimental
    Cohort 3: Dose 3

    Participants will be administered Dose 3 of GSK4528287.

    Drug: GSK4528287

  • Experimental
    Cohort 4: Dose 4

    Participants will be administered Dose 4 of GSK4528287.

    Drug: GSK4528287

  • Experimental
    Cohort 5: Dose 5

    Participants will be administered Dose 5 of GSK4528287.

    Drug: GSK4528287

  • Experimental
    Cohort 6: Dose 6

    Participants will be administered Dose 6 of GSK4528287.

    Drug: GSK4528287

  • Placebo comparator
    Placebo

    Participants will receive Placebo.

    Drug: Placebo

Interventions

  • DrugGSK4528287

    GSK4528287 will be administered.

  • DrugPlacebo

    Placebo will be administered.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.

    Time frame: Up to Day 351 (End of follow up period)

  2. Number of Participants with Serious Adverse Events (SAE)

    An SAE is defined as any untoward medical occurrence that, at any dose, meets one or more of the criteria: Results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant.

    Time frame: Up to Day 351 (End of follow up period)

  3. Number of Participants with Clinically Significant Changes in Laboratory Values

    Number of participants with clinically significant changes in laboratory values (hematology, chemistry, urinalysis, and virology) will be assessed.

    Time frame: Up to Day 351 (End of follow up period)

  4. Number of Participants with Clinically Significant Changes in Vital Signs

    Number of participants with clinically significant changes in vital signs will be assessed.

    Time frame: Up to Day 351 (End of follow up period)

  5. Number of Participants with Clinically Significant Changes in Telemetry

    Number of participants with clinically significant changes in telemetry will be assessed.

    Time frame: On Day 1

  6. Number of Participants with Clinically Significant Changes in 12 lead Electrocardiogram (ECG)

    Number of participants with clinically significant changes in 12 lead ECG will be assessed.

    Time frame: Up to Day 351 (End of follow up period)

Secondary outcomes

  1. Area under concentration-time curve (AUC) of GSK4528287

    Blood sample will be collected to evaluate plasma concentration of AUC of GSK4528287.

    Time frame: Up to Day 337

  2. Maximum concentration (Cmax) of GSK4528287

    Blood sample will be collected to evaluate plasma concentration of Cmax of GSK4528287.

    Time frame: Up to Day 337

  3. Time to maximum concentration (Tmax) of GSK4528287

    Blood sample will be collected to evaluate plasma concentration of Tmax of GSK4528287.

    Time frame: Up to Day 337

  4. Apparent terminal phase half life (T-half) of GSK4528287

    Blood sample will be collected to evaluate plasma concentration of T-half of GSK4528287.

    Time frame: Up to Day 337

  5. Clearance (CL) of GSK4528287

    Blood sample will be collected to evaluate plasma concentration of CL of GSK4528287.

    Time frame: Up to Day 337

  6. Bioavailability of GSK4528287

    Blood sample will be collected to evaluate plasma concentration of SC bioavailability of GSK4528287.

    Time frame: Up to Day 337

  7. Number of Participants with Confirmed Positive and Negative anti-GSK4528287 Antibodies

    Number of participants with confirmed positive and negative anti-GSK4528287 Antibodies will be assessed.

    Time frame: Up to Day 211

07

Study locations

1 site
  • GSK Investigational Site
    Cambridge, CB2 0GG, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Apr 2026, 17 months.

Of 58 industry-sponsored phase 1 interventional studies under Colitis, Ulcerative, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 18. This study's 17 months is above that.

Counting every sponsor, half of 84 studies reached it within 13 months; a quarter within 8 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2024
First posted
Nov 8, 2024
StartActual
Nov 18, 2024
Primary completionActual
Apr 23, 2026
CompletionEst.
Mar 11, 2027
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06681181
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Nov 8, 2024
Start date
Nov 18, 2024
Primary completion
Apr 23, 2026
Completion
Mar 11, 2027 (estimated)
Last update
Aug 26, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion